The biology of the sodium iodide symporter and its potential for targeted gene delivery

Current Cancer Drug Targets

Volumn 10, Issue 2, 2010, Pages 242-267

  Hingorani, M ^a   Spitzweg, C ^b   Vassaux, G ^c   Newbold, K ^d   Melcher, A ^e   Pandha, H ^f   Vile, R ^g   Harrington, K ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c HÔTEL DIEU   (France)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f UNIVERSITY OF SURREY   (United Kingdom)

^g MAYO CLINIC   (United States)

Author keywords

Adenovirus; Gene therapy; Measles virus; Radioiodide; Radiotherapy; Sodium iodide symporter

Indexed keywords

IODINE 124; IODINE 125; IODINE 131; RADIOISOTOPE; RHENIUM 186; SODIUM IODIDE SYMPORTER; TECHNETIUM 99M; TROGLITAZONE; VIRUS VECTOR;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; COLORECTAL CANCER; CYTOKINE PRODUCTION; DIAGNOSTIC VALUE; DNA METHYLATION; DNA SEQUENCE; ELECTROPORATION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HEAD AND NECK CANCER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOLECULAR CLONING; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROGNOSIS; RADIATION DOSE; REVIEW; THYROID CANCER; THYROID GLAND; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; VIRUS REPLICATION;

ANIMALS; GENE THERAPY; HUMANS; MICE; NEOPLASMS; RATS; SYMPORTERS;

EID: 77950687906     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910791054194     Document Type: Review

References (194)

1. Dohan, O.; De la Vieja, A.; Paroder, V.; Riedel, C.; Artani, M.; Reed, M.; Ginter, C. S.; Carrasco, N. The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr. Rev. 2003, 24, 48-77.
2. Haq, M. S.; Harmer, C. Thyroid cancer: an overview. Nucl. Med. Commun. 2004, 25, 861-867.
3. Baumann, E. Uber den Jodgehalt der Schilddrusen von Menchen und tieren. Hoppe-Seyler's Zeitschrift fur Physiologische Chemie 1986, 22, 1-17.
4. Spitzweg, C.; Harrington, K. J.; Pinke, L. A.; Vile, R. G.; Morris, J. C. Clinical review 132: The sodium iodide symporter and its potential role in cancer therapy. J. Clin. Endocrinol. Metab. 2001, 86, 3327-3335.
5. Eskandari, S.; Loo, D. D.; Dai, G.; Levy, O.; Wright, E. M.; Carrasco, N. Thyroid Na+/I- symporter. Mechanism, stoichiometry, and specificity. J. Biol. Chem. 1997, 272, 27230-27238.
6. Scott, D. A.; Wang, R.; Kreman, T. M.; Sheffield, V. C.; Karniski, L. P. The Pendred syndrome gene encodes a chloride-iodide transport protein. Nat. Genet. 1999, 21, 440-443.
7. Dohán, O.; Portulano, C.; Basquin, C.; Reyna-Neyra, A.; Amzel, L. M.; Carrasco, N. The Na+/I symporter (NIS) mediates electroneutral active transport of the environmental pollutant perchlorate. Proc. Natl. Acad. Sci. USA 2007, 104, 20250-20255.
8. Ris-Stalpers, C. Physiology and pathophysiology of the DUOXes. Antioxid Redox Signal. 2006, 8, 1563-1572.
9. Dai, G.; Levy, O.; Carrasco, N. Cloning and characterization of the thyroid iodide transporter. Nature 1996, 379, 458-460.
10. Smanik, P. A.; Liu, Q.; Furminger, T. L.; Ryu, K.; Xing, S.; Mazzaferri, E. L.; Jhiang, S. M. Cloning of the human sodium iodide symporter. Biochem. Biophys. Res. Commun. 1996, 226, 339-345.
11. Levy, O.; Dai, G.; Riedel, C.; Ginter, C. S.; Paul, E. M.; Lebowitz, A. N.; Carrasco, N. Characterization of the thyroid Na/I symporter with an anti-COOH terminus antibody. Proc. Natl. Acad. Sci. USA 1997, 94, 5568-5573.
12. Smanik, P. A.; Ryu, K. Y.; Theil, K. S.; Mazzaferri, E. L.; Jhiang, S. M. Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology 1997, 138, 3555-3558.
13. Fujiwara, H.; Tatsumi, K.; Miki, K.; Harada, T.; Miyai, K.; Takai, S.; Amino, N. Congenital hypothyroidism caused by a mutation in the Na+/I- symporter. Nat. Genet. 1997, 16, 124-125.
14. De la Vieja, A.; Reed, M. D.; Ginter, C. S.; Carrasco, N. Amino acid residues in transmembrane segment IX of the Na+/I- symporter play a role in its Na+ dependence and are critical for transport activity. J. Biol. Chem. 2007, 282, 25290-25298.
15. Dohán, O.; Gavrielides, M. V.; Ginter, C.; Amzel, L. M.; Carrasco, N. Na+/I- symporter activity requires a small and uncharged amino acid residue at position 395. Mol. Endocrinol. 2002, 16, 1893-1902.
16. Ohno, M.; Zannini, M.; Levy, O.; Carrasco, N.; Di Lauro, R. The paired-domain transcription factor Pax8 binds to the upstream enhancer of the rat sodium/iodide symporter gene and participates in both thyroid-specific and cyclic-AMP-dependent transcription. Mol. Cell. Biol. 1999, 19, 2051-2060.
17. Cass, L. A.; Summers, S. A.; Prendergast, G. V.; Backer, J. M.; Birnbaum, M. J.; Meinkoth, J. L. Protein kinase A-dependent and - independent signaling pathways contribute to cyclic AMP-stimulated proliferation. Mol. Cell Biol. 1999, 19, 5882-5891.
18. Armstrong, R.; Wen, W.; Meinkoth, J.; Taylor, S.; Montminy, M. A refractory phase in cyclic AMP-responsive transcription requires down regulation of protein kinase A. Mol. Cell. Biol. 1995, 15, 1826-1832.
19. Taki, K.; Kogai, T.; Kanamoto, Y.; Hershman, J. M.; Brent, G. A. A thyroid-specific far upstream enhancer in the human sodium/ iodide symporter gene requires Pax-8 binding and cyclic adenosine 3', 5'-monophosphate response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells. Mol. Endocrinol. 2002, 16, 2266-2282.
20. Iacovelli, L.; Capobianco, L.; Salvatore, L.; Sallese, M.; D'Ancona, G.; De Blasi, A. Thyrotropin activates mitogen-activated protein kinase pathway in FRTL-5 by a cAMP-dependent protein kinase A-independent mechanism. Mol. Pharmacol. 2001, 60, 924-933.
21. Chun, J. T.; Di Dato, V.; D'Andrea, B.; Zannini, M.; Di Lauro, R. The CRE-like element inside the 50-upstream region of the rat sodium/ iodide symporter gene interacts with diverse classes of b-Zip molecules that regulate transcriptional activities through strong synergy with Pax-8. Mol. Endocrinol. 2004, 18, 2817-2829.
22. Correze, C.; Blondeau, J. P.; Pomerance, M. The thyrotropin receptor is not involved in the activation of p42/p44 mitogen-activated protein kinases by thyrotropin preparations in Chinese hamster ovary cells expressing the human thyrotropin receptor. Thyroid 2000, 10, 747-752.
23. Medina, D. L.; Santisteban, P. Thyrotropin-dependent proliferation of in vitro rat thyroid cell systems. Eur. J. Endocrinol. 2000, 143, 161-178.
24. Pomerance, M.; Abdullah, H. B.; Kamerji, S.; Correze, C.; Blondeau, J. P. Thyroid-stimulating hormone and cyclic AMP activate p38 mitogen-activated protein kinase cascade. Involvement of protein kinase A, rac1 and reactive oxygen species. J. Biol. Chem. 2000, 25, 40539-40548.
25. Garcia, B.; Santisteban, P. PI3K is involved in the IGF-1 inhibition of TSH-induced sodium/iodide symporter gene expression. Mol. Endocrinol. 2002, 16, 342-352.
26. Cass, L. A.; Meinkoth, J. L. Ras signaling through PI3K confers hormone-independent proliferation that is compatible with differentiation. Oncogene 2000, 19, 924-932.
27. Pekary, A. E.; Hershman, J. M. Tumor necrosis factor, ceramide, transforming growth factor-beta1, and aging reduce Na+/I- symporter messenger ribonucleic acid levels in FRTL-5 cells. Endocrinology 1998, 139, 703-712.
28. Pekary, A. E.; Levin, S. R.; Johnson, D. G.; Berg, L.; Hershman, J. M. Tumor necrosis factor-alfa (TNF-alfa) and transforming growth factor beta1 (TGF-beta1) inhibit the expression and activity of Na+/K+ATPase in FRTL-5 rat thyroid cells. J. Interferon Cytokine Res. 1997, 4, 185-195.
29. Costamagna, E.; Garcia, B.; Santisteban, P. The functional interaction between the paired domain transcription factor Pax8 and Smad3 is involved in transforming growth factorbeta repression of the sodium/iodide symporter gene. J. Biol. Chem. 2004, 279, 3439-3446.
30. Behr, M.; Schmitt, T. L.; Espinoza, C. R.; Loos, U. Cloning of a functional promoter of the human sodium/iodide symporter gene. Biochem. J. 1998, 331, 359-363.
31. Ryu, K. Y.; Tong, Q.; Jhiang, S. M. Promoter characterization of the human Na/I symporter. J. Clin. Endocrinol. Metab. 1998, 83, 3247-3251.
32. Tong, Q.; Ryu, K. Y.; Jhiang, S. M. Promoter characterization of the rat Na/I symporter gene. Biochem. Biophys. Res. Commun. 1997, 239, 34-41.
33. Endo, T.; Kaneshige, M.; Nakazato, M.; Ohmori, M.; Harri, N.; Onaya, T. Thyroid transcription factor-1 activates the promoter activity of rat Na/I symporter gene. Mol. Endocrinol. 1997, 11, 1747-1755.
34. Ohmori, M.; Endo, T.; Harii, N.; Onaya, T. A novel thyroid transcription factor is essential for thyrotropin induced upregulation of Na/I symporter gene expression. Mol. Endocrinol. 1998, 12, 727-736.
35. Schmitt, L. T.; Espinoza, C. R.; Loos, U. Characterization of a thyroid-specific and cyclic adenosine monophosphate-responsive enhancer far upstream from the human sodium iodide symporter gene. Thyroid 2002, 12, 273-278.
36. Vassart, G.; Dumont, J. E. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr. Rev. 1992, 13, 596-611.
37. Laglia, G.; Zeiger, M. A.; Leipricht, A.; Caturegli, P.; Levine, M. A.; Kohn, L. D.; Saji, M. Increased cyclic adenosine 3',5'-monophosphate inhibits G protein-coupled activation of phospholipase C in rat FRTL-5 thyroid cells. Endocrinology 1996, 137, 3170-3176.
38. Saito, T.; Endo, T.; Kawaguchi, A.; Ikeda, M.; Nakazato, M.; Kogai, T.; Onaya, T. Increased expression of the Na/I symporter in cultured human thyroid cells exposed to thyrotropin and in Graves' thyroid tissue. J. Clin. Endocrinol. Metab. 1997, 82, 3331-3336.
39. Uyttersprot, N.; Pelgrims, N.; Carrasco, N.; Gervy, C.; Maenhaut, C.; Dumont, J. E.; Miot, F. Moderate doses of iodide in vivo inhibit cell proliferation and the expression of thyroperoxidase and Na//I symporter mRNAs in dog thyroid. Mol. Cell. Endocrinol. 1997, 131, 195-203.
40. Levy, O.; De la Vieja, A.; Ginter, C. S.; Riedel, C.; Dai, G.; Carrasco, N. N-linked glycosylation of the thyroid Na+/I- symporter (NIS). Implications for its secondary structure model. J. Biol. Chem. 1998, 273, 22657-22663.
41. Riedel, C.; Levy, O.; Carrasco, N. Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. J. Biol. Chem. 2001, 276, 21458-21463.
42. Kogai, T.; Endo, T.; Saito, T.; Miyazaki, A.; Kawaguchi, A.; Onaya, T. Regulation by thyroid-stimulating hormone of sodium/ iodide symporter gene expression and protein levels in FRTL-5 cells. Endocrinology 1997, 138, 2227-2232.
43. Paire, A.; Bernier-Valentin, F.; Selmi-Ruby, S.; Rousset, B. Characterization of the rat thyroid iodide transporter using anti-peptide antibodies. J. Biol. Chem. 1997, 272, 18245-18249.
44. Dohán, A.; Carrasco, N. Advances in Na+/I- symporter (NIS) research in the thyroid and beyond. Mol. Cell. Endocrinol. 2003, 213, 59-70.
45. Kogai, T.; Curcio, F.; Hyman, S.; Cornford, E. M.; Brent, G. A.; Hershman, J. M. Induction of follicle formation in long-term cultured normal human thyroid cells treated with thyrotropin stimulates iodide uptake but not sodium/iodide symporter messenger RNA and protein expression. J. Endocrinol. 2000, 167, 125-135.
46. Kaminsky, S. M.; Levy, O.; Salvador, C.; Dai, G.; Carrasco, N. Na/I symporter activity is present in membrane vesicles from thyrotropin- deprived non-I- transporting cultured thyroid cells. Proc. Natl. Acad. Sci. USA 1994, 91, 3789-3793.
47. Yokomori, N.; Tawata, M.; Saito, T.; Shimura, H.; Onaya, T. Regulation of the rat thyrotropin receptor gene by the methylationsensitive transcription factor GA-binding protein. Mol. Endocrinol. 1998, 12, 1241-1249.
48. Glavy, J. S.; Wu, S. M.; Wang, P. J.; Orr, G. A.; Wolkoff, A. W. Down-regulation by extracellular ATP of rat hepatocyte organic anion transport is mediated by serine phosphorylation of oatp1. J. Biol. Chem. 2000, 275, 1479-1484.
49. Krantz, D. E.; Waites, C.; Oorschot, V.; Liu, Y.; Wilson, R. I.; Tan, P. K.; Klumperman, J.; Edwards, R. H. A phosphorylation site regulates sorting of the vesicular acetylcholine transporter to dense core vesicles. J. Cell. Biol. 2000, 149, 379-396.
50. Ramamoorthy, S.; Blakely, R. D. Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science 1999, 285, 763-766.
51. De la Vieja, A.; Dohán, O.; Levy, O.; Carrasco, N. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol. Rev. 2000, 80, 1083-1095.
52. Msaouel, P.; Iankov, I. D.; Allen, C.; Aderca, I.; Federspiel, M. J.; Tindall, D. J.; Morris, J. C.; Koutsilieris, M.; Russell, S. J.; Galanis, E. Mol. Ther. 2009, 17, 2041-2048.
53. Fanning, A. S.; Anderson, J. M. PDZ domains: fundamental building blocks in the organization of protein complexes at the plasma membrane. J. Clin. Invest. 1999, 103, 767-772.
54. Perego, C.; Vanoni, C.; Villa, A.; Longhi, R.; Kaech, S. M.; Frohli, E.; Hajnal, A.; Kim, S. K.; Pietrini, G. PDZ-mediated interactions retain the epithelial GABA transporter on the basolateral surface of polarized epithelial cells. EMBO J. 1999, 18, 2384-2393.
55. Marks, M. S.; Ohno, H.; Kirchhausen, T.; Bonifacino, J. S. Protein sorting by tyrosine-based signals: adapting to the Ys and wherefores. Trends Cell Biol. 1997, 7, 124-128.
56. Piguet, V.; Gu, F.; Foti, M.; Demaurex, N.; Gruenberg, J.; Carpentier, J. L.; Trono, D. Nef-induced CD4 degradation: a diacidicbased motif in Nef functions as a lysosomal targeting signal through the binding of β-COP in endosomes. Cell 1999, 97, 63-73.
57. Voorhees, P.; Deignan, E.; Van Donselaar, E.; Humphrey, J.; Marks, M. S.; Peters, P. J.; Bonifacino, J. S. An acidic sequence within the cytoplasmic domain of furin functions as a determinant of trans-Golgi network localization and internalization from the cell surface. EMBO J. 1995, 14, 4961-4975.
58. Waites, C. L.; Mehta, A.; Tan, P. K.; Thomas, G.; Edwards, R. H.; Krantz, D. E. An acidic motif retains vesicular monoamine transporter 2 on large dense core vesicles. J. Cell Biol. 2001, 152, 1159-1168.
59. Hertz, S.; Roberts, A.; Salter, W. T. Radioactive iodine as an indicator in thyroid physiology. IV. The metabolism of iodine in Graves' disease. J. Clin. Invest. 1942, 21, 25-29.
60. Lazar, V.; Bidart, J-M.; Caillou, B.; Mahe, C.; Lacroix, L.; Filetti, S.; Schlumberger, M. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroidspecific genes. J. Clin. Endocrinol. Metab. 1999, 84, 3228-3234.
61. Trapasso, F.; Iuliano, R.; Chiefari, E.; Arturi , F.; Stella, A.; Filetti, S.; Fusco, A.; Russo, D. Iodide symporter gene expression in normal and transformed rat thyroid cells. Eur. J. Endocrinol. 1999, 140, 447-451.
62. Park, H. -J.; Kim, J. Y.; Park, K. Y.; Gong, G.; Hong, S. J.; Ahn, I.-M. Expression of human sodium iodide symporter mRNA in primary and metastatic papillary thyroid carcinomas. Thyroid 2000, 10, 211-217.
63. Saito, T.; Endo, T.; Kawaguchi, A.; Ikeda, M.; Katoh, R.; Kawaoi, A.; Muramatsu, A.; Onaya. T. Increased expression of the sodium/ iodide symporter in papillary thyroid carcinomas. J. Clin. Invest. 1998, 101, 1296-1300.
64. Dohán, O.; Baloch, Z.; Bánrévi, Z.; Livolsi, V.; Carrasco, N. Rapid communication: predominant intracellular overexpression of the Na(+)/I(-) symporter (NIS) in a large sampling of thyroid cancer cases. J. Clin. Endocrinol. Metab. 2001, 86, 2697-2700.
65. Wolff, J.; Chaikoff, I. L. Plasma inorganic iodide as a homeostatic regulator of thyroid function. J. Biol. Chem. 1948, 174, 555-564.
66. Raben, M. S. The paradoxical effect of thiocyanate and of thyrotropin on the organic binding of iodine by the thyroid in the presence of large amounts of iodide. Endocrinology 1949, 45, 296-304.
67. Grollman, E. F.; Smolar, A.; Ommaya, A.; Tombaccini, D.; Santisteban, P. Iodine suppression of iodide uptake in FRTL-5 thyroid cells. Endocrinology 1986, 118, 2477-2482.
68. Spitzweg, C.; Joba, W.; Morris, J. C.; Heufelder, A. E. Regulation of sodium iodide symporter gene expression in FRTL-5 rat thyroid cells. Thyroid 1999, 9, 821-830.
69. Eng, P. H. K.; Cardona, G. R.; Fang, S. L.; Previti, M.; Alex, S.; Carrasco, N.; Chin, W. W.; Braverman, L. E. Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein. Endocrinology 1999, 140, 3404-3410.
70. Eng, P. H. K.; Cardona, G. R.; Previti, M. C.; Chin, W. W.; Braverman, L. E. Regulation of the sodium iodide symporter by iodide in FRTL-5 cells. Eur. J. Endocrinol. 2001, 144, 139-144.
71. Ajjan, R. A.; Watson, P. F.; Findlay, C.; Metcalfe, R. A.; Crisp, M.; Ludgate, M.; Weetman, A. P. The sodium iodide symporter gene and its regulation by cytokines found in autoimmunity. J. Endocrinol. 1998, 158, 351-358.
72. Rasmussen, A. K.; Kayser, L.; Feldt-Rasmussen, U. Influence of tumor necrosis factor- α (TNF-α), tumor necrosis factor- β and interferon- γ, separately and added together with interleukin-1β, on the function of cultured human thyroid cells. J. Endocrinol. 1994, 143, 359-365.
73. Caturegli, P.; Hejazi, M.; Suzuki, K.; Dohan, O.; Carrasco, N.; Kohn, L. D.; Rose, N. R. Hypothyroidism in transgenic mice expressing IFN-γ in the thyroid. Proc. Natl. Acad. Sci. USA 2000, 97, 1719-1724.
74. Santoro, M.; Melillo, R. M.; Grieco, M.; Berlingieri, M. T.; Vecchio, G.; Fusco, A. The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. Cell Growth Differ. 1993, 4, 77-84.
75. Knauf, J. A.; Ouyang, B.; Croyle, M.; Kimura, E.; Fagin, J. A. Acute expression of RET/PTC induces isozyme-specific activation and subsequent downregulation of PKCepsilon in PCCL3 thyroid cells. Oncogene 2003, 22, 6830-6838.
76. Mitsutake, N.; Knauf, J. A.; Mitsutake, S.; Mesa, C., Jr.; Zhang, L.; Fagin, J. A. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res. 2005, 65, 2465-2473.
77. - targeting to the membrane. Endocr. Relat. Cancer 2006, 13, 257-269.
78. Schmutzler, C.; Winzer, R.; Meissner-Weigl, J.; Kohrle, J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem. Biophys. Res. Commun. 1997, 240, 832-838.
79. Jeong, H.; Kim, Y. R.; Kim, K. N.; Choe, J. G.; Chung, J. K.; Kim, M. K. Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nucl. Med. Biol. 2006, 33, 875-882.
80. Simon, D.; Korber, C.; Krausch, M.; Segering, J.; Groth, P.; Gorges, R.; Grunwald, F.; Muller-Gartner, H. W.; Schmutzler, C.; Kohrle, J.; Roher, H. D.; Reiners, C. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur. J. Nucl. Med. Mol. Imaging 2002, 29, 775-782.
81. Marques, A. R.; Espadinha, C.; Catarino, A. L.; Moniz, S.; Pereira, T.; Sobrinho, L. G.; Leite, V. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J. Clin. Endocrinol. Metab. 2002, 87, 3947-3952.
82. Castro, P.; Rebocho, A. P.; Soares, R. J.; Magalhaes, J.; Roque, L.; Trovisco, V.; Vieira de Castro, I.; Cardoso-de-Oliveira, M.; Fonseca, E.; Soares, P.; Sobrino-Simoes, M. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 2006, 91, 213-220.
83. Park, J. W.; Zarnegar, R.; Kanauchi, H.; Wong, M. G.; Hyun, W. C.; Ginzinger, D. G.; Lobo, M.; Cotter, P.; Duh, Q. Y.; Clark, O. H. Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 2005, 15, 222-231.
84. Ohta, K.; Endo, T.; Haraguchi, K.; Hershman, J. M.; Onaya, T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 2001, 86, 2170-2177.
85. Marks, P.; Rifkind, R. A.; Richon, V. M.; Breslow, R.; Miller, T.; Kelly, W. K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 2001, 1, 194-202.
86. Kitazono, M.; Robey, R.; Zhan, Z.; Sarlis, N. J.; Skarulis, M. C.; Aikou, T.; Bates, S.; Fojo, T. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the NaC/IK symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 2001, 86, 3430-3435.
87. Furuya, F.; Shimura, H.; Suzuki, H.; Taki, K.; Ohta, K.; Haraguchi, K.; Onaya, T.; Endo, T.; Kobayashi, T. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/ iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 2004, 145, 2865-2875.
88. Fortunati, N.; Catalano, M. G.; Arena, K.; Brignardello, E.; Piovesan, A.; Boccuzzi, G. Valproic acid induces the expression of the NaC/IK symporter and iodine uptake in poorly differentiated thyroid cancer cells. J. Clin. Endocrinol. Metab. 2004, 89, 1006-1009.
89. Shen, W. T.; Wong, T. S.; Chung, W. Y.; Wong, M. G.; Kebebew, E.; Duh, Q. Y.; Clark, O. H. Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells. Surgery 2005, 138, 979-985.
90. Baylin, S. B. Tying it all together: epigenetics, genetics, cell cycle, and cancer. Science 1997, 277, 1948-1949.
91. Venkataraman, G. M.; Yatin, M.; Marcinek, R.; Ain, K. B. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I- symporter gene methylation status. J. Clin. Endocrinol. Metab. 1999, 84, 2449-2457.
92. Neumann, S.; Schuchardt, K.; Reske, A.; Emmrich, P.; Paschke, R. Lack of correlation for sodium iodide symporter mRNA and protein expression and analysis of sodium iodide symporter promoter methylation in benign cold thyroid nodules. Thyroid 2004, 14, 99-111.
93. Ulianich, L.; Suzuki, K.; Mori, A.; Nakazato, M.; Pietrarelli, M.; Goldsmith, P.; Pacifico, F.; Consiglio, E.; Formisano, S.; Kohn, L. D. Follicular thyroglobulin (TG) suppression of thyroid-restricted genes involves the apical membrane asialoglycoprotein receptor and TG phosphorylation. J. Biol. Chem. 1999, 274, 25099-25107.
94. Furlanetto, T. W.; Nguyen, L. Q.; Jameson, J. L. Estradiol increases proliferation and down-regulates the sodium/iodide symporter gene in FRTL-5 cells. Endocrinology 1999, 140, 5705-5711.
95. Brown-Grant, K. Extra-thyroidal iodide concentrating mechanisms. Physiol. Rev. 1961, 41, 189-213.
96. Carrasco, N. Iodide transport in the thyroid gland. Biochim. Biophys. Acta 1993, 1154, 65-82.
97. Halmi, N. S. Thyroidal iodide transport. Vitam. Horm. 1961, 19, 133-163.
98. Ajjan, R. A.; Kamaruddin, N. A.; Crisp, M.; Watson, P. F.; Ludgate, M.; Weetman, A. P. Regulation and tissue distribution of the human sodium iodide symporter gene. Clin. Endocrinol. (Oxf) 1998, 49, 517-523.
99. Spitzweg, C.; Joba, W.; Eisenmenger, W.; Heufelder, A. E. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary DNA from salivary gland, mammary gland, and gastric mucosa. J. Clin. Endocrinol. Metab. 1998, 83, 1746-1751.
100. Cho, J. Y.; Leveille, R.; Kao, R.; Rousset, B.; Parlow, A. F.; Burak Jr, W. E.; Mazzaferri, E. L.; Jhiang, S. M. Hormonal regulation of radioiodide uptake activity and Na+/I- symporter expression in mammary glands. J. Clin. Endocrinol. Metab. 2000, 85, 2936-2943.
101. Spitzweg, C.; Dutton, C. M.; Castro, M. R.; Bergert, E. R.; Goellner, J. R.; Heufelder, A. E.; Morris, J. C. Expression of the sodium iodide symporter in human kidney. Kidney Int. 2001, 59, 1013-1023.
102. Taurog, A.; Dorris, M. L.; Lamas, L. Comparison of lactoperoxidase- and thyroid peroxidase-catalyzed iodination and coupling. Endocrinology 1974, 94, 1286-1294.
103. Tazebay, U. H.; Wapnir, I. L.; Levy, O.; Dohan, O.; Zuckier, L. S.; Zhao, Q. H.; Deng, H. F.; Amenta, P. S.; Fineberg, S.; Pestell, R. G.; Carrasco, N. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat. Med. 2000, 6, 871-878.
104. Rillema, J. A.; Yu, T. X.; Jhiang, S. M. Effect of prolactin on sodium iodide symporter expression in mouse mammary gland explants. Am. J. Physiol. Endocrinol. Metab. 2000, 279, E769-E772.
105. Jhiang, S. M.; Cho, J. Y.; Ryu, K. Y.; DeYoung, B. R.; Smanik, P. A.; McGauchy, V. R.; Fischer, A. H.; Mazzaferri, E. L. An immunohistochemical study of Na+/I- symporter in human thyroid tissues and salivary gland tissues. Endocrinology 1998, 139, 4416-4419.
106. Vayre, L.; Sabourin, J. C.; Caillou, B.; Ducreux, M.; Schlumberger, M.; Bidart, J. M. Immunohistochemical analysis of Na+/I- symporter distribution in human extra-thyroid tissues. Eur. J. Endocrinol. 1999, 141, 382-386.
107. Wapnir, I. L.; van de Rijn, M.; Nowels, K.; Amenta, P. S.; Walton, K.; Montgomery, K.; Greco, R. S.; Dohan, O.; Carrasco, N. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J. Clin. Endocrinol. Metab. 2003, 88, 1880-1888.
108. Moon, D. H.; Lee, S. J.; Park, K. Y.; Park, K. K.; Ahn, S. H.; Pai, M. S.; Chang, H.; Lee, H. K.; Ahn, I.M. Correlation between 99mTc-pertechnetate uptake and expression of human sodium iodide symporter gene in breast tumor tissues. Nucl. Med. Biol. 2001, 28, 829-834.
109. Wapnir, I. L.; Goris, M.; Yudd, A.; Dohan, O.; Adelman, D.; Nowels, K.; Carrasco, N. The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively downregulated in the thyroid. Clin. Cancer Res. 2004, 10, 4294-4302.
110. Knostman, K. A.; McCubrey, J. A.; Morrison, C. D.; Zhang, Z.; Capen, C. C.; Jhiang, S. M. PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer. BMC Cancer 2007, 7, 137.
111. Kogai, T.; Schultz, J. J.; Johnson, L. S.; Huang, M.; Brent, G. A. Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line. Proc. Natl. Acad. Sci. USA 2000, 97, 8519-8524.
112. Kogai, T.; Kanamoto, Y.; Li, A. I.; Che, L. H.; Ohashi, E.; Taki, K.; Chandraratna, R. A.; Saito, T.; Brent, G. A. Differential regulation of sodium/iodide symporter (NIS) gene expression by nuclear receptor ligands in MCF-7 breast cancer cells. Endocrinology 2005, 146, 3059-3069.
113. Tanosaki, S.; Ikezoe, T.; Heaney, A.; Said, J. W.; Dan, K.; Akashi, M.; Koeffler, H. P. Effect of ligands of nuclear hormone receptors on sodium/iodide symporter expression and activity in breast cancer cells. Breast Cancer Res. Treat. 2003, 79, 335-345.
114. Kogai, T.; Kanamoto, Y.; Che, L. H.; Taki, K.; Moatamed, F.; Schultz, J. J.; Brent, G. A. Systemic retinoic acid treatment induces sodium/iodide symporter expression and radioiodide uptake in mouse breast cancer models. Cancer Res. 2004, 64, 415-422.
115. Agarwal, C.; Chandraratna, R. A.; Johnson, A. T.; Rorke, E. A.; Eckert, R. L. AGN193109 is a highly effective antagonist of retinoid action in human ectocervical epithelial cells. J. Biol. Chem. 1996, 271, 12209-12212.
116. Blaner, W. S. Cellular metabolism and actions of 13-cis retinoic acid. J. Am. Acad. Dermatol. 2001, 45, S129-S135.
117. Kogai, T.; Kanamoto, Y.; Brent, G. A. The modified firefly luciferase reporter gene (lucC) but not Renilla luciferase is induced by all-trans retinoic acid in MCF-7 breast cancer cells. Breast Cancer Res. Treat. 2003, 78, 119-126.
118. Dentice, M.; Luongo, C.; Elefante, A.; Romino, R.; Ambrosio, R.; Vitale, M.; Rossi, G.; Fenzi, G.; Salvatore, D. Transcription factor Nkx-2.5 induces sodium/iodide symporter gene expression and participates in retinoic acid- and lactation-induced transcription in mammary cells. Mol. Cell. Biol. 2004, 24, 7863-7877.
119. Kogai, T.; Taki, K.; Brent, G. A. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr. Relat. Cancer 2006, 13, 797-826.
120. Unterholzner, S.; Willhauck, M. J.; Cengic, N.; Schütz, M.; Göke, B.; Morris, J. C.; Spitzweg, C. Dexamethasone stimulation of retinoic Acid-induced sodium iodide symporter expression and cytotoxicity of 131-I in breast cancer cells. J. Clin. Endocrinol. Metab. 2006, 91, 69-78.
121. Willhauck, M. J.; Sharif-Samani, B.; Senekowitsch-Schmidtke, R.; Wunderlich, N.; Göke, B.; Morris, J. C.; Spitzweg, C. Functional sodium iodide symporter expression in breast cancer xenografts in vivo after systemic treatment with retinoic acid and dexamethasone. Breast Cancer Res. Treat. 2008, 109, 263-272.
122. Pasieka, J. L.; McEwan, A. J.; Rorstad, O. The palliative role of 131I-MIBG and 111-In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. Surgery 2004, 136, 1218-1226.
123. Liepe, K.; Kotzerke, J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl. Med. Commun. 2007, 28, 623-630.
124. Shelley, M. D.; Mason, M. D. Radium-223 for men with hormonerefractory prostate cancer and bone metastases. Lancet Oncol. 2007, 8, 564-567.
125. Taggart, D.; Dubois, S.; Matthay, K. K. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q. J. Nucl. Med. Mol. Imaging 2008, 52, 403-418.
126. Illidge, T. M.; Bayne, M. C. Antibody therapy of lymphoma. Expert Opin. Pharmacother. 2001, 2, 953-961.
127. Spitzweg, C.; Zhang, S.; Bergert, E. R.; Castro, M. R.; McIver, B.; Heufelder, A. E.; Tindall, D. J.; Young, C. Y.; Morris, J. C. Prostate specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res. 1999, 59, 2136-2141.
128. Spitzweg, C.; O'Connor, M. K.; Bergert, E. R.; Tindall, D. J.; Young, C. Y.; Morris, J. C. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res. 2000, 15, 6526-6530.
129. Spitzweg, C.; Dietz, A. B.; O'Connor, M. K.; Bergert, E. R.; Tindall, D. J.; Young, C. Y.; Morris, J. C. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther. 2001, 8, 1524-1531.
130. Mothersill, C.; Seymour, C. B. Radiation-induced bystander effects-implications for cancer. Nat. Rev. Cancer 2004, 4, 158-164.
131. Little, J. B.; Azzam, E. I.; De Toledo, S. M.; Nagasawa, H. Bystander effects: intercellular transmission of radiation damage signals. Radiat. Prot. Dosimet. 2002, 99, 159-162.
132. Shimura, H.; Haraguchi, K.; Myazaki, A.; Endo, T.; Onaya, T. Iodide uptake and experimental 131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I- symporter gene. Endocrinology 1997, 138, 4493-4496.
133. Riesco-Eizaguirre, G.; Santisteban, P. A perspective view of sodium iodide symporter research and its clinical implications. Eur. J. Endocrinol. 2006, 155, 495-512.
134. Cho, J. -Y.; Xing, S.; Liu, X.; Buckwalter, T. L.; Hwa, L.; Sferra, T. J.; Chiu, I. M.; Jhiang, S. M. Expression and activity of human Na1/I2 symporter in human glioma cells by adenovirus-mediated gene delivery. Gene Ther. 2000, 7, 740-749.
135. Mandell, R. B.; Mandell, L. Z.; Link, C. J. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res. 1999, 59, 661-668.
136. Boland, A.; Ricard, M.; Opolon, P.; Bidart, J. M.; Yeh, P.; Filetti, S.; Schlumberger, M.; Perricaudet, M. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res. 2000, 60, 3484-3492.
137. Nakamoto, Y.; Saga, T.; Misaki, T.; Kobayashi, H.; Sato, N.; Ishimori, T.; Kosugi, S.; Sakahara, H.; Konishi, J. Establishment and characterization of a breast cancer cell line expressing Na+/I- symporters for radioiodide concentrator gene therapy. J. Nucl. Med. 2000, 41, 1898-1904.
138. Cho, Y. -C.; Shen, D. H. Y.; Yang, W.; Williams, B.; Buckwalter, T. L. F.; La Perle, K. M. D.; Hinkle, G.; Pozderac, R.; Kloos, R.; Nagaraja, H. N.; Barth R. F.; Jhiang, S. M. In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal models of intracerebral gliomas. Gene Ther. 2002, 9, 1139-1145.
139. Kakinuma, H.; Bergert, E. R.; Spitzweg, C.; Cheville, J. C.; Lieber, M. M.; Morris, J. C. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res. 2003, 63, 7840-7844.
140. Sieger, S.; Jiang, S.; Schönsiegel, F.; Eskerski, H.; Kübler, W.; Altmann, A.; Haberkorn, U. Tumour-specific activation of the sodium/ iodide symporter gene under control of the glucose transporter gene 1 promoter (GTI-1.3). Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 748-756.
141. Haberkorn, U.; Kinscherf, R.; Kissel, M.; Kübler, W.; Mahmut, M.; Sieger, S.; Eisenhut, M.; Peschke, P.; Altmann, A. Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose. Gene Ther. 2003, 10, 774-780.
142. Faivre, J.; Clerc, J.; Gérolami, R.; Hervé, J.; Longuet, M.; Liu, B.; Roux, J.; Moal, F.; Perricaudet, M.; Bréchot, C. Long-term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in wistar rats. Cancer Res. 2004, 64, 8045-8051.
143. Gaut, A. W.; Niu, G.; Krager, K. J.; Graham, M. M.; Trask, D. K.; Domann, F. E. Genetically targeted radiotherapy of head and neck squamous cell carcinoma using the sodium-iodide symporter (NIS). Head Neck 2004, 26, 265-271.
144. Schipper, M. L.; Weber, A.; Béhé, M.; Göke, R.; Joba, W.; Schmidt, H.; Bert, T.; Simon, B.; Arnold, R.; Heufelder, A. E.; Behr, T. M. Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells. Cancer Res. 2003, 63, 1333-1338.
145. Cengic, N.; Baker, C. H.; Schütz, M.; Göke, B.; Morris, J. C.; Spitzweg, C. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression. J. Clin. Endocrinol. Metab. 2005, 90, 4457-4464.
146. Scholz, I. V.; Cengic, N.; Baker, C. H.; Harrington, K. J.; Maletz, K.; Bergert, E. R.; Vile, R.; Göke, B.; Morris, J. C.; Spitzweg, C. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Ther. 2005, 12, 272-280.
147. Dwyer, R. M.; Bergert, E. R.; O'Connor, M. K.; Gendler, S. J.; Morris, J. C. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin. Cancer Res. 2005, 11, 1483-1489.
148. Dwyer, R. M.; Bergert, E. R.; O'Connor, M. K.; Gendler, S. J.; Morris, J. C. Adenovirus-mediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors. Hum. Gene Ther. 2006, 17, 661-668.
149. Dwyer, R. M.; Bergert, E. R.; O'Connor, M. K.; Gendler, S. J.; Morris, J. C. Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice. Gene Ther. 2006, 13, 60-66.
150. Chen, R. F.; Li, Z. H.; Pan, Q. H.; Zhou, J. J.; Tang, Q. B.; Yu, F. Y.; Zhou, Q. B.; Wang, J.; Chen, J. S. In vivo radioiodide imaging and treatment of pancreatic cancer xenografts after MUC1 promoter- driven expression of the human sodium-iodide symporter. Pancreatology 2007, 7, 505-513.
151. Spitzweg, C.; Baker, C. H.; Bergert, E. R.; O'Connor, M. K.; Morris, J. C. Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression. Hum. Gene Ther. 2007, 18, 916-924.
152. Willhauck, M. J.; Sharif Samani, B. R.; Klutz, K.; Cengic, N.; Wolf, I.; Mohr, L.; Geissler, M.; Senekowitsch-Schmidtke, R.; Göke, B.; Morris, J. C.; Spitzweg, C. Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma. Gene Ther. 2008, 15, 214-223.
153. Dwyer, R. M.; Schatz, S. M.; Bergert, E. R.; Myers, R. M.; Harvey, M. E.; Classic, K. L.; Blanco, M. C.; Frisk, C. S.; Marler, R. J.; Davis, B. J.; O'Connor, M. K.; Russell, S. J.; Morris, J. C. A preclinical large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer. Mol. Ther. 2005, 12, 835-841.
154. Merron, A.; Peerlinck, I.; Martin-Duque, P.; Burnet, J.; Quintanilla, M.; Mather, S.; Hingorani, M.; Harrington, K.; Iggo, R.; Vassaux, G. SPECT/CT imaging of oncolytic adenovirus propagation in tumours in vivo using the Na/I symporter as a reporter gene. Gene Ther. 2007, 14, 1731-1738.
155. Peerlinck, I.; Merron, A.; Baril, P.; Conchon, S.; Martin-Duque, P.; Hindorf, C.; Burnet, J.; Quintanilla, M.; Hingorani, M.; Iggo, R.; Lemoine, N. R.; Harrington, K.; Vassaux, G. Targeted radionuclide therapy using a Wnt-targeted replicating adenovirus encoding the Na/I symporter. Clin. Cancer Res. 2009, 15, 6595-6601.
156. Dingli, D.; Peng, K. W.; Harvey, M. E.; Greipp, P. R.; O'Connor, M. K.; Cattaneo, R.; Morris, J. C.; Russell, S. J. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004, 103, 1641-1646.
157. Hasegawa, K.; Pham, L.; O'Connor, M. K.; Federspiel, M. J.; Russell, S. J.; Peng, K. W. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin. Cancer Res. 2006, 12, 1868-1875.
158. Carlson, S. K.; Classic, K. L.; Hadac, E. M.; Bender, C. E.; Kemp, B. J.; Lowe, V. J.; Hoskin, T. L.; Russell, S. J. In vivo quantitation of intratumoral radioisotope uptake using micro-single photon emission computed tomography/computed tomography. Mol. Imaging Biol. 2006, 8, 324-332.
159. Carlson, S. K.; Classic, K. L.; Hadac, E. M.; Dingli, D.; Bender, C. E.; Kemp, B. J.; Russell, S. J. Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene. AJR Am. J. Roentgenol. 2009, 192, 279-287.
160. Russell, S. J.; Peng, K. W. Measles virus for cancer therapy. Curr. Top. Microbiol. Immunol. 2009, 330, 213-241.
161. Dupertuis, Y. M.; Xiao, W. H.; De Tribolet, N.; Pichard, C.; Slosman, D. O.; Bischof Delaloye, A.; Buchegger, F. Unlabelled iododeoxyuridine increases the rate of uptake of [125I]iododeoxyuridine in human xenografted glioblastomas. Eur. J. Nucl. Med. Mol. Imaging 2002, 29, 499-505.
162. O'Hare, N. J.; Murphy, D.; Malone, J. F. Thyroid dosimetry of adult European populations. Br. J. Radiol. 1998, 71, 535-543.
163. Mazzaferri, E. L.; Kloos, R. T. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J. Clin. Endocrinol. Metab. 2001, 86, 1447-1463.
164. Vini, L.; Harmer, C. Radioiodine treatment for differentiated thyroid cancer. Clin. Oncol. (R Coll. Radiol. ) 2000, 12, 365-372.
165. Alexander, C.; Bader, J. B.; Schaefer, A.; Finke, C.; Kirsch, C. M. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J. Nucl. Med. 1998, 39, 1551-1554.
166. Benua, R.; Cicale, N. R.; Sonenberg, M.; Rawson, R. W. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am. J. Roentgenol. Radium Ther. Nucl. Med. 1962, 87, 171-182.
167. Maxon, H. R. III.; Englaro, E. E.; Thomas, S. R.; Hertzberg, V. S.; Hinnefeld, J. D.; Chen, L. S.; Smith, H.; Cummings, D.; Aden, M. D. Radioiodine-131 therapy for well differentiated thyroid cancer - a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J. Nucl. Med. 1992, 33, 1132-1136.
168. Gershengorn, M. C.; Izumi, M.; Robbins, J. Use of lithium as an adjunct to radioiodine therapy of thyroid carcinoma. J. Clin. Endocrinol. Metab. 1976, 42, 105-111.
169. Movius, E. G.; Robbins, J.; Pierce, L. R.; Reynolds, J. C.; Keenan, A. M.; Phyillaier, M. A. The value of lithium in radioiodine therapy of thyroid carcinoma. In: Medeiros-Neto, G.; Gaitan, E., Eds. Frontiers in Thyroidology. Plenum Press: New York, 1996, Vol.2, pp. 1269-1272.
170. Koong, S. S.; Reynolds, J. C.; Movius, E. G.; Keenan, A. M.; Ain, K. B.; Lakshmanan, M. C.; Robbins, J. Lithium as a potential adjuvant to 131I therapy of metastatic well differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 1999, 84, 912-916.
171. Liu, Y. Y.; van der Pluijm, G.; Karperien, M.; Stokkel, M. P.; Pereira, A. M.; Morreau, J.; Kievit, J.; Romijn, J. A.; Smit, J. W. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies. Clin. Endocrinol. (Oxf). 2006, 64, 617-624.
172. Elisei, R.; Vivaldi, A.; Ciampi, R.; Faviana, P.; Basolo, F.; Santini, F.; Traino, C.; Pacini, F.; Pinchera, A. Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid. J. Clin. Endocrinol. Metab. 2006, 91, 2389-2395.
173. Huang, M.; Batra, R. K.; Kogai, T.; Lin, Y. Q.; Hershman, J. M.; Lichtenstein, A.; Sharma, S.; Zhu, L. X.; Brent, G. A.; Dubinett, S. M. Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther. 2001, 8, 612-618.
174. Boland, A.; Magnon, C.; Filetti, S.; Bidart, J. M.; Schlumberger, M.; Yeh, P.; Perricaudet, M. Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers. Thyroid 2002, 12, 19-26.
175. Smit, J. W.; Schroder-van der Elst, J. P.; Karperien, M.; Que, I.; Stokkel, M.; van der Heide, D.; Romijn, J. A. Iodide kinetics and experimental 131I therapy in a xenotransplanted human sodium- iodide symporter-transfected human follicular thyroid carcinoma cell line. J. Clin. Endocrinol. Metab. 2002, 87, 1247-1253.
176. Dadachova, E.; Bouzahzah, B.; Zuckier, L. S.; Pestell, R. G. Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS). Nucl. Med. Biol. 2002, 29, 13-18.
177. Shen, D. H.; Marsee, D. K.; Schaap, J.; Yang, W.; Cho, J. Y.; Hinkle, G.; Nagaraja, H. N.; Kloos, R. T.; Barth, R. F.; Jhiang, S. M. Effects of dose, intervention time, and radionuclide on sodium iodide symporter (NIS)-targeted radionuclide therapy. Gene Ther. 2004, 11, 161-169.
178. Zuckier, L. S.; Dohan, O.; Li, Y.; Chang, C. J.; Carrasco, N.; Dadachova, E. Kinetics of perrhenate uptake and comparative biodistribution of perrhenate, pertechnetate, and iodide by NaI symporter-expressing tissues in vivo. J. Nucl. Med. 2004, 45, 500-507.
179. Dadachova, E.; Nguyen, A.; Lin, E. Y.; Gnatovskiy, L.; Lu, P.; Pollard, J. W. Treatment with rhenium-188-perrhenate and iodine- 131 of NIS-expressing mammary cancer in a mouse model remarkably inhibited tumor growth. Nucl. Med. Biol. 2005, 32, 695-700.
180. Willhauck, M. J.; Sharif Samani, B. R.; Gildehaus, F. J.; Wolf, I.; Senekowitsch-Schmidtke, R.; Stark, H. J.; Göke, B.; Morris, J. C.; Spitzweg, C. Application of 188rhenium as an alternative radionuclide for treatment of prostate cancer after tumor-specific sodium iodide symporter gene expression. J. Clin. Endocrinol. Metab. 2007, 92, 4451-4458.
181. Carlin, S.; Akabani, G.; Zalutsky, M. R. In vitro cytotoxicity of (211)At-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter. J. Nucl. Med. 2003, 44, 1827-1838.
182. Petrich, T.; Quintanilla-Martinez, L.; Korkmaz, Z.; Samson, E.; Helmeke, H. J.; Meyer, G. J.; Knapp, W. H.; Pötter, E. Effective cancer therapy with the alpha-particle emitter [211At]astatine in a mouse model of genetically modified sodium/iodide symporter-expressing tumors. Clin. Cancer Res. 2006, 12, 1342-1348.
183. Spitzweg, C.; Scholz, I. V.; Bergert, E. R.; Tindall, D. J.; Young, C. Y.; Göke, B.; Morris, J. C. Retinoic acid-induced stimulation of sodium iodide symporter expression and cytotoxicity of radioiodine in prostate cancer cells. Endocrinology 2003, 144, 3423-3432.
184. Lim, S. J.; Paeng, J. C.; Kim, S. J.; Kim, S. Y.; Lee, H.; Moon, D. H. Enhanced expression of adenovirus-mediated sodium iodide symporter gene in MCF-7 breast cancer cells with retinoic acid treatment. J. Nucl. Med. 2007, 48, 398-404.
185. Harrington, K. J.; Melcher, A.; Vassaux, G.; Pandha, H. S.; Vile, R. G. Exploiting synergies between radiation and oncolytic viruses. Curr. Opin. Mol. Ther. 2008, 10, 362-370.
186. Hingorani, M.; White, C. L.; Zaidi, S.; Merron, A.; Peerlinck, I.; Gore, M. E.; Nutting, C. M.; Pandha, H. S.; Melcher, A. A.; Vile, R. G.; Vassaux, G.; Harrington, K. J. Radiation-mediated upregulation of gene expression from replication-defective adenoviral vectors: implications for sodium iodide symporter gene therapy. Clin. Cancer Res. 2008, 14, 4915-4924.
187. Hingorani, M.; White, C. L.; Merron, A.; Peerlinck, I.; Gore, M. E.; Slade, A.; Scott, S. D.; Nutting, C. M.; Pandha, H. S.; Melcher, A. A.; Vile, R. G.; Vassaux, G.; Harrington, K. J. Inhibition of repair of radiation-induced DNA damage enhances gene expression from replication-defective adenoviral vectors. Cancer Res. 2008, 68, 9771-9778.
188. Kassis, A. I.; Adelstein, S. J. Radiobiologic principles in radionuclide therapy. J. Nucl. Med. 2005, 46(Suppl 1), 4S-12S.
189. Walicka, M. A.; Vaidyanathan, G.; Zalutsky, M. R.; Adelstein, S. J.; Kassis, A. I. Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211. Radiat. Res. 1998, 150, 263-268.
190. Kassis, A. I.; Harris, C. R.; Adelstein, S. J.; Ruth, T. J.; Lambrecht, R.; Wolf, A. P. The in vitro radiobiology of astatine-211 decay. Radiat. Res. 1986, 105, 27-36.
191. Charlton, D. E.; Kassis, A. I.; Adelstein, S. J. A comparison of experimental and calculated survival curves for V79 cells grown as monolayers or in suspension exposed to alpha irradiation from 212Bi distributed in the growth medium. Radiat. Prot. Dosim. 1994, 52, 311-315.
192. Dingli, D.; Russell, S. J.; Morris, J. C. 3rd. In vivo imaging and tumor therapy with the sodium iodide symporter. J. Cell Biochem. 2003, 90, 1079-1086.
193. Barton, K. N.; Tyson, D.; Stricker, H.; Lew, Y. S.; Heisey, G.; Koul, S.; de la Zerda, A.; Yin, F. F.; Yan, H.; Nagaraja, T. N.; Randall, K. A.; Jin, G. K.; Fenstermacher, J. D.; Jhiang, S.; Ho Kim, J.; Freytag, S. O.; Brown, S. L. GENIS: gene expression of sodium iodide symporter for noninvasive imaging of gene therapy vectors and quantification of gene expression in vivo. Mol. Ther. 2003, 8, 508-518.
194. Barton, K. N.; Stricker, H.; Brown, S. L.; Elshaikh, M.; Aref, I.; Lu, M.; Pegg, J.; Zhang, Y.; Karvelis, K. C.; Siddiqui, F.; Kim, J. H.; Freytag, S. O.; Movsas, B. Phase I study of non-invasive imaging of adenovirus-mediated gene expression in the human prostate. Mol. Ther. 2008, 16, 1761-1769.